Double-blind comparative study of sitafloxacin versus levofloxacin in patients with respiratory tract infection
スポンサーリンク
概要
- 論文の詳細を見る
The clinical efficacy and safety of sitafloxacin (STFX), a fluoroquinolone compound, and levofloxacin (LVFX) were objectively compared in the treatment of patients with pneumonia, secondary infection, or acute exacerbation of chronic respiratory tract disease in a double-blind, randomized, group-comparative study. Patients were treated for 7 days with either STFX 50mg orally twice daily (STFX group) or LVFX 100mg three times daily (LVFX group).<BR>The clinical efficacy rate at the end of treatment in 208 evaluable patients was 92.5%(99/107) in the STFXgroup and 92.1%(93/101) in the LVFX group. STFX was found to be not inferior to LVFX. The clinical efficacy rate was 96.4%(53/55) in the STFX group and 94.0%(47/50) in the LVFX group for pneumonia and 88.5%(46/52) in the STFX group and 90.2%(46/51) in the LVFX group for secondary infection or acute exacerbation of chronic respiratory tract disease. Eradication in 97 patients evaluable for bacteriological response was 78.4%(40/51) in the STFX group and 80.4%(37/46) in the LVFX group. Based on bacterium disappearance by causative bacterium, 95.0%(19/20) of Gram-positive bacteria was eradicated in the STFX group and 87.5%(21/24) in the LVFX group. For Gram-negative bacteria, 79.4%(27/34) was eradicated in the STFX group and 81.5%(22/27) in the LVFX group. The incidence of adverse drug reaction was 29.8%(34/114) in the STFX group and 25.9%(30/116) in the LVFX group.<BR>These results suggest that a 50mg oral dose of STFX twice daily for 7 days is clinically useful in the treatment of respiratory tract infection.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.